Press Release
Zydus' Nesher Pharmaceuticals gets USFDA final approval for Dextroamphetamine Sulfate Extended-Release Capsules29-06-2017
29-06-2017
Troubles behind it, Cadila surges ahead
Cadila hopes to double its revenue from the US in three years28-06-2017
Press Release
Zydus receives final approval from the USFDA for Oxybutynin Chloride Extended-Release Tablets28-06-2017
Cadila Healthcare Board Nod For Up To Fund Raising Up To Rs 18,500 Crore
Zydus Cadila group has global operations in four continents spread across the US, Europe, Latin America and South Africa and 25 other emerging markets.26-06-2017
Focus on Cadila's fund-raising plans
The board of directors of Cadila Healthcare will meet on Monday to consider a proposal to raise funds by issue of equity shares/convertible bonds/debentures through qualified institutional...23-06-2017
USFDA closes audit of Zydus' Moraiya facility
Healthcare player Zydus Cadila (Cadila Healthcare Ltd) on Wednesday informed that it had received an audit report from the US drug regulator, the US Food and Drug Administration (USFDA), for the...21-06-2017
Board Meeting On June 26, 2017
A meeting of the Board of Directors is scheduled to be held on Monday, June 26, 2017, to consider the following proposals: (i)to raise funds by issue of Equity Shares / Convertible Bonds / Debentures through Qualified Institutional Placement [QIP] / GDR / ADR, subject to approval of the shareholders, (ii)to issue Secured / Unsecured Redeemable Non-Convertible Debentures / Foreign Currency Bonds on Private Placement Basis, subject to approval of the shareholders and...21-06-2017